Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists hunt for clues to why phage therapy works in stubborn lung infections

NCT ID NCT07076238

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This study is looking for biological markers (biomarkers) that can show whether phage therapy is working against hard-to-treat bacterial lung infections. Researchers will collect blood and airway samples from 100 adults with nontuberculous mycobacterial lung disease who are being considered for phage therapy. They will compare samples from those who receive phage therapy and those who do not, focusing on changes in the lung microbiome, immune response, and other factors. The goal is to identify signs that predict improvement in infection symptoms or lab results after 6-8 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

Conditions

Explore the condition pages connected to this study.